Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced
Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end
Anticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) monotherapy clinical data in first quarter of 2023
Conference call scheduled for today at 4:30 p.m. ET
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on MacroGenics’ website for 30 days following the call.
https://finance.yahoo.com/news/macrogenics-provides-corporate-third-quarter-200100804.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.